Anti-Perforin antibody [CB5.4] (ab16074)
Key features and details
- Rat monoclonal [CB5.4] to Perforin
- Suitable for: IP, ICC, WB, IHC-Fr, IHC-P, ICC/IF
- Reacts with: Mouse
- Isotype: IgG2a
Overview
-
Product name
Anti-Perforin antibody [CB5.4]
See all Perforin primary antibodies -
Description
Rat monoclonal [CB5.4] to Perforin -
Host species
Rat -
Tested applications
Suitable for: IP, ICC, WB, IHC-Fr, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
Recombinant fragment, corresponding to amino acids 98 - 534 of Mouse Perforin.
-
Epitope
This antibody recognizes mouse perforin, region amino acids 402-534. -
General notes
This product was changed from ascites to tissue culture supernatant on 31st May 2019. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
CB5.4 -
Isotype
IgG2a -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab16074 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
Use at an assay dependent concentration.
|
|
ICC |
Use at an assay dependent concentration.
|
|
WB | (1) |
Use at an assay dependent concentration.
|
IHC-Fr |
Use at an assay dependent concentration.
|
|
IHC-P | (3) |
Use at an assay dependent concentration.
|
ICC/IF | (1) |
Use at an assay dependent concentration.
|
Notes |
---|
IP
Use at an assay dependent concentration. |
ICC
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. |
IHC-Fr
Use at an assay dependent concentration. |
IHC-P
Use at an assay dependent concentration. |
ICC/IF
Use at an assay dependent concentration. |
Target
-
Function
Plays a key role in secretory granule-dependent cell death, and in defense against virus-infected or neoplastic cells. Plays an important role in killing other cells that are recognized as non-self by the immune system, e.g. in transplant rejection or some forms of autoimmune disease. Can insert into the membrane of target cells in its calcium-bound form, oligomerize and form large pores. Promotes cytolysis and apoptosis of target cells by facilitating the uptake of cytotoxic granzymes. -
Involvement in disease
Defects in PRF1 are the cause of hemophagocytic lymphohistiocytosis familial type 2 (FHL2) [MIM:603553]; also known as HPLH2. Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically heterogeneous, rare autosomal recessive disorder. It is characterized by immune dysregulation with hypercytokinemia and defective natural killer cell function. The clinical features of the disease include fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, hypofibrinogenemia, and neurological abnormalities ranging from irritability and hypotonia to seizures, cranial nerve deficits, and ataxia. Hemophagocytosis is a prominent feature of the disease, and a non-malignant infiltration of macrophages and activated T lymphocytes in lymph nodes, spleen, and other organs is also found. -
Sequence similarities
Belongs to the complement C6/C7/C8/C9 family.
Contains 1 C2 domain.
Contains 1 EGF-like domain.
Contains 1 MACPF domain. -
Domain
The C2 domain mediates calcium-dependent binding to lipid membranes. A subsequent conformation change leads to membrane insertion of beta-hairpin structures and pore formation. The pore is formed by transmembrane beta-strands. -
Post-translational
modificationsN-glycosylated. -
Cellular localization
Cytoplasmic granule lumen. Secreted. Cell membrane. Endosome lumen. Stored in cytoplasmic granules of cytolytic T-lymphocytes and secreted into the cleft between T-lymphocyte and target cell. Inserts into the cell membrane of target cells and forms pores. Membrane insertion and pore formation requires a major conformation change. May be taken up via endocytosis involving clathrin-coated vesicles and accumulate in a first time in large early endosomes. - Information by UniProt
-
Database links
- Entrez Gene: 18646 Mouse
- SwissProt: P10820 Mouse
- Unigene: 240313 Mouse
-
Alternative names
- Cytolysin antibody
- FLH2 antibody
- HPLH2 antibody
see all
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (29)
ab16074 has been referenced in 29 publications.
- Liu X et al. Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-Immunotherapy. Small 17:e2005993 (2021). PubMed: 33682329
- Liu X et al. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Adv Sci (Weinh) 8:2002147 (2021). PubMed: 33747719
- Koda Y et al. CD8+ tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells. Nat Commun 12:4474 (2021). PubMed: 34294714
- Ravindran Menon D et al. EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals (Basel) 14:N/A (2021). PubMed: 34832863
- Xu Y et al. MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8+ T lymphocytes in human diffuse large B cell lymphoma. J Exp Clin Cancer Res 39:238 (2020). PubMed: 33168024